Literature DB >> 11408499

Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort.

R T Poon1, I O Ng, S T Fan, E C Lai, C M Lo, C L Liu, J Wong.   

Abstract

PURPOSE: This study aims to clarify the clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma (HCC). PATIENTS AND METHODS: The clinicopathologic features of 5-year survivors and disease-free survivors were elucidated in a cohort of 230 patients prospectively observed for > 5 years (64 to 192 months) after curative resection of HCC.
RESULTS: The incidence of 5-year overall and disease-free survivors were 37% (85 of 230) and 20% (45 of 230), respectively. Clinicopathologic features associated with 5-year survivors included female sex (P =.024), preoperative serum albumin > or= 40 g/L (P =.033), AST < 50 u/L (P =.001), tumor < 5 cm (P =.001), solitary tumor (P =.035), encapsulated tumor (P =.021), no venous invasion (P =.001), no microsatellite nodule (P =.001), and early pathologic tumor-node-metastasis (pTNM) stage (I or II, P <.001). Features favoring 5-year disease-free survivors were preoperative serum AST < 50 u/L (P =.007), tumor < 5 cm (P =.005), encapsulated tumor (P =.007), no venous invasion (P <.001), no microsatellite nodule (P =.001), and early pTNM stage (I or II, P <.001). By multivariate analysis, pTNM stage was the only significant predictive factor for both overall and disease-free survival.
CONCLUSION: This study shows that long-term disease-free survival > 5 years after resection of HCC can be achieved in patients with favorable tumor characteristics. Early pTNM stage was the most reliable predictor of both long-term overall and disease-free survivors.

Entities:  

Mesh:

Year:  2001        PMID: 11408499     DOI: 10.1200/JCO.2001.19.12.3037

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  51 in total

Review 1.  Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Surgical management of hepatocellular carcinoma.

Authors:  Tony Cy Pang; Vincent Wt Lam
Journal:  World J Hepatol       Date:  2015-02-27

3.  Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.

Authors:  A Grieco; M Pompili; G Caminiti; L Miele; M Covino; B Alfei; G L Rapaccini; G Gasbarrini
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

4.  Transcript AA454543 is a novel prognostic marker for hepatocellular carcinoma after curative partial hepatectomy.

Authors:  Siu Tim Cheung; Jenny C Y Ho; Ka Ling Leung; Xin Chen; Daniel Y T Fong; Samuel So; Sheung Tat Fan
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

5.  A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection.

Authors:  Saadettin Kilickap; Ayse Kars; Erhan Hamaloglu; Halis Simsek
Journal:  Med Oncol       Date:  2009-08-18       Impact factor: 3.064

6.  Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system.

Authors:  Albert C Y Chan; Sheung Tat Fan; Ronnie T P Poon; Tan To Cheung; Kenneth S H Chok; See Ching Chan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-02       Impact factor: 3.647

7.  Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases.

Authors:  Xin-Da Zhou; Zhao-You Tang; Zeng-Chen Ma; Jia Fan; Zhi-Quan Wu; Lun-Xiu Qin; Jian Zhou; Yao Yu; Hui-Chuan Sun; Shuang-Jian Qiu
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-18       Impact factor: 4.553

8.  Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study.

Authors:  Zheng-Gang Ren; Zhi-Ying Lin; Jing-Lin Xia; Sheng-Long Ye; Zeng-Chen Ma; Qing-Hai Ye; Lun-Xiu Qin; Zhi-Quan Wu; Jia Fan; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

9.  microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma.

Authors:  Julja Burchard; Chunsheng Zhang; Angela M Liu; Ronnie T P Poon; Nikki P Y Lee; Kwong-Fai Wong; Pak C Sham; Brian Y Lam; Mark D Ferguson; George Tokiwa; Ryan Smith; Brendan Leeson; Rebecca Beard; John R Lamb; Lee Lim; Mao Mao; Hongyue Dai; John M Luk
Journal:  Mol Syst Biol       Date:  2010-08-24       Impact factor: 11.429

10.  Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters.

Authors:  Ke Hao; John M Luk; Nikki P Y Lee; Mao Mao; Chunsheng Zhang; Mark D Ferguson; John Lamb; Hongyue Dai; Irene O Ng; Pak C Sham; Ronnie T P Poon
Journal:  BMC Cancer       Date:  2009-11-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.